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Identity 
Other names: CaT1; ECaC2; CATL; ABP/ZF; 
LP6728; ZFAB 
HGNC (Hugo): TRPV6 
Location: 7q34 
Local order: Colocalized with another Ca2+-selective 
epithelial channel gene, TRPV5. 
DNA/RNA 
Description 
TRPV6 gene consists of 15 exons and 14 introns 
including a coding, and a 5'-/3'- non-coding region.  
The regions encoding the ankyrin repeats, 6 trans-
membrane domains and a pore region are indicated. 
Several VDREs (vitamin D responsive element) have 
been identified in its promoter region. 
A haplotype containing 3 non-synonymous 
polymorphisms (C157R+M378V+M681T) repre-sent a 
recent positive selection in human evolution. The same 
haplotype seems to be associated with renal calcium 
stone formation. 
Transcription 
There is an alterative splice variant which missed 25-
192 (a.a.). In EST database, there seems to be at least 
one more variant using different exon 1 (V2) and a 
variant starting from another site (P3) just upstream of 
exon 2 (V3). 
 
Schematic representation of human TRPV6 gene and neighbouring genes. 
 
Genomic structure of human TRPV6. The coding region is shown by open bars. The non-translated regions are shown by filled bars. 
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Protein 
 
Schematic representation of TRPV6 protein. Four subunits 
makes one channel pore. Several ankyrin repeats, one N-
glycosylation site and several calmodulin binding sites (CaM) 
are indicated. 
Description 
Glycosylated membrane protein (725 a.a., MW ~70 
kDa) with 6 transmembrane regions and a pore-forming 
loop. N- and C-terminal tails are in cytoplasmic side. 
This protein forms a Ca2+-selective ion channel in the 
plasma membrane. TRPV6 interacts with 
calmodulin which contribute to the intracellular 
Ca2+-dependent inactivation to avoid an increase 
of free Ca2+ concentration. The ankyrin repeats 
may play a role in the interaction between 
subunits. TRPV6 can form a homo-tetramer as 
well as a hetero-tetramer with TRPV5, which 
exhibits distinct channel properties. 
Expression 
Highly expressed in placenta, moderately expressed in 
exocrine pancreas, mammary gland and salivary gland. 
Highly induced in small intestine under low calcium 
conditions or by 1,25-dihydroxyvitamin D3 treatment. 
Highly induced in prostate, breast and other cancer 
tissues during tumor progression. 
Localisation 
Plasma membrane. Localized in the apical membrane 
of the epithelial cells in the duodenum, and 
syncytiotrophoblasts in placenta. 
Function 
Apical Ca2+ entry pathway for total body calcium 
homeostasis in the small intestine under the control of 
1,25-dihydroxyvitamin D3. TRPV6 likely also be 
involved in the placental Ca2+ transport from mother to 
fetus to maintain fetal bone mineralization. 
TRPV6 may play a role in the Ca2+ entry pathway 
essential for keratinocyte differentiation. Although its 
exact function in cancer cells and tumor progression is 
still under investigation, TRPV6 is involved in an 
increase in proliferation and apoptotic resistance in 
cancer cells. 
Homology 





Expression of TRPV6 may be a predictor for prostate 
cancer progression since TRPV6 mRNA and protein 
levels are elevated in prostatic carcinoma compared to 
benign prostatic hyperplasia and positively correlated 
with Gleason grade/score in prostatic carcinoma. 
TRPV6 is involved in an increase in proliferation ad 
apoptotic resistance in cancer cells, suggesting that
TRPV6 could be a new therapeutic target for the 
treatment for advanced prostate cancer. 
Breast cancer 
Oncogenesis 
TRPV6 mRNA was also found to be increased in breast 
cancer tissues compared to normal breast tissues. 
TRPV6 could be a prognostic marker for breast cancer 
and therapeutic target for breast cancer treatment. 
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